Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
…, J Blohmer, EP Mamounas, J Bergh, V Semiglazov… - The Lancet, 2014 - thelancet.com
Background Pathological complete response has been proposed as a surrogate endpoint
for prediction of long-term clinical benefit, such as disease-free survival, event-free survival (…
for prediction of long-term clinical benefit, such as disease-free survival, event-free survival (…
[HTML][HTML] Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early …
…, EJT Rutgers, F Sedlmayer, V Semiglazov… - Annals of oncology, 2013 - Elsevier
The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel reviewed
and endorsed substantial new evidence on aspects of the local and regional therapies for …
and endorsed substantial new evidence on aspects of the local and regional therapies for …
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a …
…, JL Pedrini, B Poirier, P Morandi, V Semiglazov… - The lancet …, 2012 - thelancet.com
Background Studies with pertuzumab, a novel anti-HER2 antibody, show improved efficacy
when combined with the established HER2-directed antibody trastuzumab in breast cancer …
when combined with the established HER2-directed antibody trastuzumab in breast cancer …
[HTML][HTML] Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer
…, J Baselga, SB Kim, J Ro, V Semiglazov… - New England journal …, 2015 - Mass Medical Soc
Background In patients with metastatic breast cancer that is positive for human epidermal
growth factor receptor 2 (HER2), progression-free survival was significantly improved after first-…
growth factor receptor 2 (HER2), progression-free survival was significantly improved after first-…
[HTML][HTML] Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast …
…, EJT Rutgers, F Sedlmayer, V Semiglazov… - Annals of oncology, 2015 - Elsevier
The 14th St Gallen International Breast Cancer Conference (2015) reviewed substantial
new evidence on locoregional and systemic therapies for early breast cancer. Further …
new evidence on locoregional and systemic therapies for early breast cancer. Further …
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
…, J Domont, LM Tseng, G Kunz, JH Sohn, V Semiglazov… - The Lancet, 2012 - thelancet.com
Background The anti-HER2 monoclonal antibody trastuzumab and the tyrosine kinase inhibitor
lapatinib have complementary mechanisms of action and synergistic antitumour activity …
lapatinib have complementary mechanisms of action and synergistic antitumour activity …
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally …
L Gianni, W Eiermann, V Semiglazov, A Manikhas… - The Lancet, 2010 - thelancet.com
Background The monoclonal antibody trastuzumab has survival benefit when given with
chemotherapy to patients with early, operable, and metastatic breast cancer that has HER2 (…
chemotherapy to patients with early, operable, and metastatic breast cancer that has HER2 (…
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo …
…, D Miles, SB Kim, YH Im, SA Im, V Semiglazov… - The Lancet …, 2020 - thelancet.com
Background CLEOPATRA was a phase 3 study comparing the efficacy and safety of pertuzumab,
trastuzumab, and docetaxel with placebo, trastuzumab, and docetaxel in patients with …
trastuzumab, and docetaxel with placebo, trastuzumab, and docetaxel in patients with …
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind …
SM Swain, SB Kim, J Cortés, J Ro, V Semiglazov… - The lancet …, 2013 - thelancet.com
Background CLEOPATRA is a phase 3 study to compare the efficacy and safety of pertuzumab,
trastuzumab, and docetaxel with placebo, trastuzumab, and docetaxel in patients with …
trastuzumab, and docetaxel with placebo, trastuzumab, and docetaxel in patients with …
[HTML][HTML] Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast …
The 17th St Gallen International Breast Cancer Consensus Conference in 2021 was held
virtually, owing to the global COVID-19 pandemic. More than 3300 participants took part in this …
virtually, owing to the global COVID-19 pandemic. More than 3300 participants took part in this …
